AGEN - Agenus Inc Stock Price, Fair Value and News

6.59USD+0.62 (+10.39%)Market Closed

Market Summary

USD6.59+0.62

Market Closed

10.39%

AGEN Stock Price

View Fullscreen

AGEN RSI Chart

AGEN Valuation

Market Cap

138.4M

Price/Earnings (Trailing)

-32.66

Price/Sales (Trailing)

0.86

EV/EBITDA

-0.71

Price/Free Cashflow

-0.65

AGEN Price/Sales (Trailing)

AGEN Profitability

Operating Margin

99.43%

EBT Margin

-74.77%

Return on Equity

-31.07%

Return on Assets

-1.65%

Free Cashflow Yield

-153.21%

AGEN Fundamentals

AGEN Revenue

Revenue (TTM)

161.4M

Rev. Growth (Yr)

22.28%

Rev. Growth (Qtr)

-66.58%

AGEN Earnings

Earnings (TTM)

-4.2M

Earnings Growth (Yr)

10.49%

Earnings Growth (Qtr)

-132.18%

Breaking Down AGEN Revenue

Last 7 days

10.0%

Last 30 days

-53.6%

Last 90 days

-43.6%

Trailing 12 Months

-77.3%

How does AGEN drawdown profile look like?

AGEN Financial Health

Current Ratio

0.24

AGEN Investor Care

Shares Dilution (1Y)

20.38%

Diluted EPS (TTM)

-12.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	161.4M	0	0	0
2023	95.0M	99.4M	100.9M	156.3M
2022	309.9M	320.1M	89.9M	98.0M
2021	84.8M	68.5M	306.7M	295.7M
2020	85.3M	96.5M	91.4M	88.2M
2019	115.0M	114.9M	122.0M	150.0M
2018	41.4M	39.8M	38.3M	36.8M
2017	43.6M	41.2M	40.1M	42.9M
2016	26.8M	27.0M	24.6M	22.6M
2015	10.2M	13.5M	18.8M	24.8M
2014	2.7M	4.9M	5.8M	7.0M
2013	3.7M	3.9M	3.7M	3.0M
2012	15.5M	15.3M	15.5M	16.0M
2011	3.1M	3.1M	3.1M	2.8M
2010	0	3.3M	3.4M	3.4M
2009	0	0	0	3.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Agenus Inc

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFÃƒÆ’Ã…Â¸ TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

CEO	Dr. Garo H. Armen Ph.D.
WEBSITE	agenusbio.com
INDUSTRY	Biotechnology
EMPLOYEES	533

Agenus Inc Frequently Asked Questions

What is the ticker symbol for Agenus Inc? What does AGEN stand for in stocks?

AGEN is the stock ticker symbol of Agenus Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agenus Inc (AGEN)?

As of Fri Jul 26 2024, market cap of Agenus Inc is 138.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGEN stock?

You can check AGEN's fair value in chart for subscribers.

Is Agenus Inc a good stock to buy?

The fair value guage provides a quick view whether AGEN is over valued or under valued. Whether Agenus Inc is cheap or expensive depends on the assumptions which impact Agenus Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGEN.

What is Agenus Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, AGEN's PE ratio (Price to Earnings) is -32.66 and Price to Sales (PS) ratio is 0.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Agenus Inc's stock?

In the past 10 years, Agenus Inc has provided -0.204 (multiply by 100 for percentage) rate of return.